Doctors aren't getting the skinny on drug side effects from pharma reps, a new study finds. Even the most serious risks are often overlooked, the survey found. And while probes of off-label marketing abound, enforcement of risk disclosures during sales visits is mostly absent.
Pharma reps have been known to chafe at time-logging rules. Keeping a journal of office visits and sample hand-outs can be such a pain--and shouldn't results speak more loudly than hash marks on a sales-call report?
More than half of pharma's top executives say it's more difficult to recruit the right people these days, according to a new report from PricewaterhouseCoopers.
It's the end of the year, and the end of the road for hundreds of Pfizer drug reps. The company is slashing its primary-care sales force by almost 20%, Bloomberg reports, taking its 3,000-strong army of reps down to around 2,400.
Technology is great when it works. For drug companies, it's even better when it blazes a trail to that elusive big game in the promotional field: The primary cared doctor.
It's the sort of code-of-practice violation that doesn't typically make headlines outside of the trade press. But this time, it's the context that counts. Just months after CEO Andrew Witty vowed to stamp out marketing missteps, GlaxoSmithKline ($GSK) was slapped on the hand by the U.K.'s self-governing pharma board for a sales rep's off-label promotion.
Abbott Laboratories ($ABT) says "no more" to gift-giving in India. The U.S.-based company, which happens to be India's biggest drugmaker, has ordered its sales reps to suspend distributing the sort of tchotchkes--pens, for instance--common in the U.S., as well as the sort of gifts more specific to India, such as electrical apppliances, Reuters reports.
Pharma reps have grown accustomed to doctors closing the door on them. First, physicians complained that too many salespeople came calling. Then, critics started questioning whether doctors should see pharma reps at all. The sum? More "appointments-only" access--and no access, period.
While U.S. doctors are seeing more pharma reps with iPads in hand, U.K. doctors are seeing fewer pharma reps, period. According to a recent survey reported at PMLive , more than half of general practitioners in Britain admitted no drug salespeople during the previous week, and another 26% saw just one.
Any doubt that the iPad is the pharma sales rep's tool of choice? No? Well, now you have the numbers to back up that belief. According to a Manhattan Research report, 65% of doctors who've seen a drug rep in person this year also saw that drug rep's iPad.